Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease defined by the proliferation of immature myeloid progenitor cells in the bone marrow that impairs normal blood cell development and leads to bone marrow failure. AML is characterized by a variety of chromosomal abnormalities and gene mutations. These abnormalities and mutations result in marked differences in response to chemotherapy and survival. The cytogenetic and molecular genetic abnormalities associated with AML are not mutually exclusive and often co-occur in leukemic cells diagnosed with the disease. Analysis of the molecular alterations associated with chromosomal and genetic abnormalities in AML could provide a basis for treatment planning and identification of biomarkers for AML treatment. Based on increasingly available molecular genetics for precision medicine, AML is being subdivided into recurrent molecular entities. Emerging therapies include daunorubicin/cytarabine, tyrosine kinase inhibitors directed against FLT3, IDH inhibitors, Bcl-2 inhibitors, metabolic inhibitors, and demethylating drugs that form the basis for innovative multimodality therapy. AML patients will benefit from some new treatments, but more affordable options are needed. One source of potential treatments with known toxicity profiles and reasonable prices is repurposing or repositioning drugs. The development of antileukemic drugs for well-defined patient subgroups must be accompanied by research and the development of biomarkers of response.
This is a preview of subscription content, log in via an institution to check access.
References
Abe-Suzuki S, Kurata M, Abe S et al (2014) CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes. Lab Investig 94:1212–1223. https://doi.org/10.1038/labinvest.2014.110
Advani AS, McDonough S, Copelan E et al (2014) SWOG0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol 167:233–237. https://doi.org/10.1111/bjh.13035
Ahn JS, Kim HJ (2022) FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. Blood Res 57:S32–S36. https://doi.org/10.5045/br.2022.2022017
Al-Harbi S, Aljurf M, Mohty M et al (2020) An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Blood Adv 4:229–238. https://doi.org/10.1182/bloodadvances.2019000168
Al-Jamal HAN, Mat Jusoh SA, Hassan R, Johan MF (2015) Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. BMC Cancer 15:869. https://doi.org/10.1186/s12885-015-1695-x
Alvarez S, Suela J, Valencia A et al (2010) DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One 5:e12197. https://doi.org/10.1371/journal.pone.0012197
Arteaga MF, Mikesch JH, Fung TK, So CWE (2015) Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies. Br J Cancer 112:413–418. https://doi.org/10.1038/bjc.2014.374
Assouline S, Culjkovic B, Cocolakis E et al (2009) Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114:257–260. https://doi.org/10.1182/blood-2009-02-205153
Assouline S, Culjkovic-Kraljacic B, Bergeron J et al (2015) A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Haematologica 100:e7–e9. https://doi.org/10.3324/haematol.2014.111245
Balgi AD, Fonseca BD, Donohue E et al (2009) Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 4:e7124. https://doi.org/10.1371/journal.pone.0007124
Boddu P, Kantarjian H, Ravandi F et al (2018) Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma 59:2238–2241. https://doi.org/10.1080/10428194.2017.1422864
Böhm A, Piribauer M, Wimazal F et al (2005) High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res 29:609–615. https://doi.org/10.1016/j.leukres.2004.10.009
Breems DA, van Putten WLJ, de Greef GE et al (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26:4791–4797. https://doi.org/10.1200/JCO.2008.16.0259
Buhagiar A, Borg J, Ayers D (2020) Overview of current microRNA biomarker signatures as potential diagnostic tools for leukaemic conditions. Noncoding RNA Res 5:22–26. https://doi.org/10.1016/j.ncrna.2020.02.001
Burnett AK, Milligan D, Prentice AG et al (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109(6):1114–1124. https://doi.org/10.1002/cncr.22496
Campo E, Swerdlow SH, Harris NL et al (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032. https://doi.org/10.1182/blood-2011-01-293050
Carson DA, Wasson DB, Beutler E (1984) Antileukemic and immunosuppressive activity of 2-chloro-2’-deoxyadenosine. Proc Natl Acad Sci 81:2232–2236. https://doi.org/10.1073/pnas.81.7.2232
Chae HD, Cox N, Dahl G et al (2018) Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget 9:4301–4317. https://doi.org/10.18632/oncotarget.23794
Chen P, Price C, Li Z et al (2013) miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia–rearranged leukemia. Proc Natl Acad Sci 110:11511–11516. https://doi.org/10.1073/pnas.1310144110
Chen X, Lin J, Qian J et al (2014) Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia. Clin Biochem 47:63–66. https://doi.org/10.1016/j.clinbiochem.2013.09.020
Chen S-L, Qin Z-Y, Hu F et al (2019) The role of the HOXA gene family in acute myeloid leukemia. Genes (Basel) 10:621. https://doi.org/10.3390/genes10080621
Chiaretti S, Gianfelici V, Ceglie G, Foà R (2014) Genomic characterization of acute leukemias. Med Princ Pract 23:487–506. https://doi.org/10.1159/000362793
Cho JW, Kim JJ, Park SG et al (2004) Identification of B-cell translocation gene 1 as a biomarker for monitoring the remission of acute myeloid leukemia. Proteomics 4:3456–3463. https://doi.org/10.1002/pmic.200400968
Claus R, Plass C, Armstrong SA, Bullinger L (2010) DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncol 6:1415–1431. https://doi.org/10.2217/fon.10.110
Cortes JE, Douglas Smith B, Wang ES et al (2018) Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol 93:1301–1310. https://doi.org/10.1002/ajh.25238
Cortes JE, Gutzmer R, Kieran MW, Solomon JA (2019a) Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat Rev 76:41–50. https://doi.org/10.1016/j.ctrv.2019.04.005
Cortes JE, Khaled S, Martinelli G et al (2019b) Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 20:984–997. https://doi.org/10.1016/S1470-2045(19)30150-0
Daver N, Schlenk RF, Russell NH, Levis MJ (2019) Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33:299–312. https://doi.org/10.1038/s41375-018-0357-9
de Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189–3199. https://doi.org/10.1038/sj.onc.1207545
de Braekeleer E, Douet-Guilbert N, de Braekeleer M (2014) RARA fusion genes in acute promyelocytic leukemia: a review. Expert Rev Hematol 7:347–357. https://doi.org/10.1586/17474086.2014.903794
Delaunay J (2003) Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML intergroup. Blood 102:462–469. https://doi.org/10.1182/blood-2002-11-3527
DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7–17. https://doi.org/10.1182/blood-2018-08-868752
Dohner K, Dohner H (2008) Molecular characterization of acute myeloid leukemia. Haematologica 93:976–982. https://doi.org/10.3324/haematol.13345
Döhner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136–1152. https://doi.org/10.1056/NEJMra1406184
Drenberg CD, Buaboonnam J, Orwick SJ et al (2016) Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemother Pharmacol 77:1231–1243. https://doi.org/10.1007/s00280-016-3038-2
Du W, Lu C, Zhu X et al (2019) Prognostic significance of CXCR4 expression in acute myeloid leukemia. Cancer Med 8:6595–6603. https://doi.org/10.1002/cam4.2535
Eriksson A, Österroos A, Hassan S et al (2015) Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia. Blood Cancer J 5:e307–e307. https://doi.org/10.1038/bcj.2015.31
Eriksson A, Chantzi E, Fryknäs M et al (2017) Towards repositioning of quinacrine for treatment of acute myeloid leukemia – promising synergies and in vivo effects. Leuk Res 63:41–46. https://doi.org/10.1016/j.leukres.2017.10.012
Falini B, Mecucci C, Tiacci E et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254–266. https://doi.org/10.1056/NEJMoa041974
Falini B, Brunetti L, Sportoletti P, Martelli MP (2020) NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood 136:1707–1721. https://doi.org/10.1182/blood.2019004226
Fiegl M, Samudio I, Clise-Dwyer K et al (2009) CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 113:1504–1512. https://doi.org/10.1182/blood-2008-06-161539
Gaidzik VI, Teleanu V, Papaemmanuil E et al (2016) RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia 30:2160–2168. https://doi.org/10.1038/leu.2016.126
Garcia-Manero G, Tambaro FP, Bekele NB et al (2012) Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 30:2204–2210. https://doi.org/10.1200/JCO.2011.38.3265
Garzon R, Volinia S, Liu CG et al (2008) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111:3183–3189. https://doi.org/10.1182/blood-2007-07-098749
Gaspar N, Hawkins DS, Dirksen U et al (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33:3036–3046. https://doi.org/10.1200/JCO.2014.59.5256
Geva M, Shouval R, Fein JA et al (2019) Lactate dehydrogenase is a key prognostic factor in acute myeloid leukemia and lymphoma patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 134:3304–3304. https://doi.org/10.1182/blood-2019-125529
Ghanem H, Kantarjian H, Ohanian M, Jabbour E (2013) The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma 54:688–698. https://doi.org/10.3109/10428194.2012.726722
Grove CS, Vassiliou GS (2014) Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech 7:941–951. https://doi.org/10.1242/dmm.015974
Gulley ML, Shea TC, Fedoriw Y (2010) Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia. J Mol Diagn 12:3–16. https://doi.org/10.2353/jmoldx.2010.090054
Harris WJ, Huang X, Lynch JT et al (2012) The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21:473–487. https://doi.org/10.1016/j.ccr.2012.03.014
Hoy SM (2019) Glasdegib: first global approval. Drugs 79:207–213. https://doi.org/10.1007/s40265-018-1047-7
Ivey A, Hills RK, Simpson MA et al (2016) Assessment of minimal residual disease in standard-risk AML. N Engl J Med 374:422–433. https://doi.org/10.1056/NEJMoa1507471
Jiang L, Deng T, Wang D, Xiao Y (2018) Elevated serum exosomal miR-125b level as a potential marker for poor prognosis in intermediate-risk acute myeloid leukemia. Acta Haematol 140:183–192. https://doi.org/10.1159/000491584
Jin Y, Lu Z, Ding K et al (2010) Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-κB pathway and generation of reactive oxygen species. Cancer Res 70:2516–2527. https://doi.org/10.1158/0008-5472.CAN-09-3950
Jin H, Zhu Y, Hong M et al (2021) Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia. Leuk Lymphoma 62:2428–2437. https://doi.org/10.1080/10428194.2021.1919660
Kadia TM, Jain P, Ravandi F et al (2016) TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes. Cancer 122:3484–3491. https://doi.org/10.1002/cncr.30203
Kantarjian H, Kadia T, DiNardo C et al (2021) Acute myeloid leukemia: current progress and future directions. Blood Cancer J 11:41. https://doi.org/10.1038/s41408-021-00425-3
Kayser S, Schlenk RF, Platzbecker U (2018) Management of patients with acute promyelocytic leukemia. Leukemia 32:1277–1294. https://doi.org/10.1038/s41375-018-0139-4
Kennedy VE, Smith CC (2020) FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol 10:612880. https://doi.org/10.3389/fonc.2020.612880
Kentsis A, Topisirovic I, Culjkovic B et al (2004) Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci 101:18105–18110. https://doi.org/10.1073/pnas.0406927102
Kerr R, Cunningham J, Bowen D (2000) Low-dose melphalan in elderly acute myeloid leukaemia: complete remissions but resistant relapse with therapy-related karyotypes. Leukemia 14:953–953. https://doi.org/10.1038/sj.leu.2401762
Kim Y, Eom JI, Jeung HK et al (2015) Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine. Biomed Pharmacother 73:87–96. https://doi.org/10.1016/j.biopha.2015.05.012
Kolla B, Halim NAA, Sachs Z et al (2019) High risk of relapse with intermediate dose cytarabine for consolidation in young favorable risk AML patients following induction with 7+3. Blood 134:3432–3432. https://doi.org/10.1182/blood-2019-123306
Kornblau SM, Banker DE, Stirewalt D et al (2007) Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 109:2999–3006. https://doi.org/10.1182/blood-2006-08-044446
Krivtsov A, Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7:823–833. https://doi.org/10.1038/nrc2253
Kumar CC (2011) Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2:95–107. https://doi.org/10.1177/1947601911408076
Lagunas-Rangel FA, Chávez-Valencia V, Gómez-Guijosa MÁ, Cortes-Penagos C (2017) Acute myeloid leukemia-genetic alterations and their clinical prognosis. Int J Hematol Oncol Stem Cell Res 11:328–339
Lara-Castillo MC, Cornet-Masana JM, Etxabe A et al (2016) Repositioning of bromocriptine for treatment of acute myeloid leukemia. J Transl Med 14:261. https://doi.org/10.1186/s12967-016-1007-5
Larrosa-Garcia M, Baer MR (2017) FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther 16:991–1001. https://doi.org/10.1158/1535-7163.MCT-16-0876
Laverdière I, Boileau M, Neumann AL et al (2018) Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Blood Cancer J 8:52. https://doi.org/10.1038/s41408-018-0087-2
Lawrie TA, Alazzam M, Tidy J et al (2016) First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 6:CD007102. https://doi.org/10.1002/14651858.CD007102.pub4
Leitch C, Osdal T, Andresen V et al (2016) Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. Oncotarget 7:8105–8118. https://doi.org/10.18632/oncotarget.6991
Lennartsson J, Rönnstrand L (2012) Stem cell factor receptor/c-kit: from basic science to clinical implications. Physiol Rev 92:1619–1649. https://doi.org/10.1152/physrev.00046.2011
Li Y, Gao L, Luo X et al (2013) Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 121:499–509. https://doi.org/10.1182/blood-2012-07-444729
Li HY, Deng DH, Huang Y et al (2015a) Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis. Eur J Haematol 94:439–448. https://doi.org/10.1111/ejh.12450
Li Z, Chen P, Su R et al (2015b) Overexpression and knockout of miR-126 both promote leukemogenesis. Blood 126:2005–2015. https://doi.org/10.1182/blood-2015-04-639062
Linch DC, Hills RK, Burnett AK et al (2014) Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood 124:273–276. https://doi.org/10.1182/blood-2014-02-554667
Lindsley RC, Mar BG, Mazzola E et al (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367–1376. https://doi.org/10.1182/blood-2014-11-610543
Liquori A, Ibañez M, Sargas C et al (2020) Acute Promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene. Cancers 12:624. https://doi.org/10.3390/cancers12030624
Liu N, Wang C, Wang L et al (2016) Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis. Int J Mol Med 37:1686–1696. https://doi.org/10.3892/ijmm.2016.2552
Liu Y, Cheng Z, Pang Y et al (2019) Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol 12:51. https://doi.org/10.1186/s13045-019-0734-5
Lu JJ, Meng LH, Cai YJ et al (2008) Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther 7:1017–1023. https://doi.org/10.4161/cbt.7.7.6035
Madaan K, Kaushik D, Verma T (2012) Hydroxyurea: a key player in cancer chemotherapy. Expert Rev Anticancer Ther 12:19–29. https://doi.org/10.1586/era.11.175
Magliano G, Bacigalupo A (2020) Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemıa of the elderly: review of the literature and perspectıves. Mediterranean J Hematol Infect Dis 12:e2020081. https://doi.org/10.4084/mjhid.2020.081
Magliulo D, Bernardi R, Messina S (2018) Lysine-specific demethylase 1A as a promising target in acute myeloid leukemia. Front Oncol 8:255. https://doi.org/10.3389/fonc.2018.00255
Marcucci G, Maharry K, Wu YZ et al (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 28:2348–2355. https://doi.org/10.1200/JCO.2009.27.3730
Martens JHA, Stunnenberg HG (2010) The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett 584:2662–2669. https://doi.org/10.1016/j.febslet.2010.04.002
Metzeler KH, Herold T, Rothenberg-Thurley M et al (2016) Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood 128:686–698. https://doi.org/10.1182/blood-2016-01-693879
Meyer SC, Levine RL (2014) Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol 15:e382–e394. https://doi.org/10.1016/S1470-2045(14)70008-7
Meyer C, Kowarz E, Hofmann J et al (2009) New insights to the MLL recombinome of acute leukemias. Leukemia 23:1490–1499. https://doi.org/10.1038/leu.2009.33
Mrózek K (2008) Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 35:365–377. https://doi.org/10.1053/j.seminoncol.2008.04.007
Mrózek K, Heerema NA, Bloomfield CD (2004) Cytogenetics in acute leukemia. Blood Rev 18:115–136. https://doi.org/10.1016/S0268-960X(03)00040-7
Muntean AG, Hess JL (2012) The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 7:283–301. https://doi.org/10.1146/annurev-pathol-011811-132434
Nagpal S, Friant S, Nakshatri H, Chambon P (1993) RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J 12:2349–2360. https://doi.org/10.1002/j.1460-2075.1993.tb05889.x
Narayan N, Morenos L, Phipson B et al (2017) Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia. Leukemia 31:808–820. https://doi.org/10.1038/leu.2016.279
Neuberger A, Oraiopoulos N, Drakeman DL (2019) Renovation as innovation: is repurposing the future of drug discovery research? Drug Discov Today 24:1–3. https://doi.org/10.1016/j.drudis.2018.06.012
Nguyen S (2002) A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 99:3517–3523. https://doi.org/10.1182/blood.V99.10.3517
Norsworthy KJ, Luo L, Hsu V et al (2019) FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin Cancer Res 25:3205–3209. https://doi.org/10.1158/1078-0432.CCR-18-3749
O’Farrell AM, Abrams TJ, Yuen HA et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605. https://doi.org/10.1182/blood-2002-07-2307
Pankey GA (2005) Tigecycline. J Antimicrob Chemother 56:470–480. https://doi.org/10.1093/jac/dki248
Papaemmanuil E, Gerstung M, Bullinger L et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209–2221. https://doi.org/10.1056/NEJMoa1516192
Paschka P, Marcucci G, Ruppert AS et al (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and leukemia group B study. J Clin Oncol 24:3904–3911. https://doi.org/10.1200/JCO.2006.06.9500
Paschka P, Schlenk RF, Gaidzik VI et al (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:3636–3643. https://doi.org/10.1200/JCO.2010.28.3762
Patel SS, Ho C, Ptashkin RN et al (2019) Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Adv 3(9):1540–1545. https://doi.org/10.1182/bloodadvances.2019000090
Perl AE, Martinelli G, Cortes JE et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 381:1728–1740. https://doi.org/10.1056/NEJMoa1902688
Pollyea DA, Amaya M, Strati P, Konopleva MY (2019) Venetoclax for AML: changing the treatment paradigm. Blood Adv 3:4326–4335. https://doi.org/10.1182/bloodadvances.2019000937
Ponnusamy K, Kohrs N, Ptasinska A et al (2015) RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1. Oncogenesis 4:e146–e146. https://doi.org/10.1038/oncsis.2015.6
Pourrajab F, Zare-Khormizi MR, Hashemi AS, Hekmatimoghaddam S (2020) Genetic characterization and risk stratification of acute myeloid leukemia. Cancer Manag Res 12:2231–2253. https://doi.org/10.2147/CMAR.S242479
Prada-Arismendy J, Arroyave JC, Röthlisberger S (2017) Molecular biomarkers in acute myeloid leukemia. Blood Rev 31:63–76. https://doi.org/10.1016/j.blre.2016.08.005
Ramsingh G, Westervelt P, McBride A et al (2014) Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Int J Hematol 99:272–278. https://doi.org/10.1007/s12185-014-1503-4
Reed DR, Elsarrag RZ, Morris AL, Keng MK (2019) Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment. Cancer Manag Res 11:8073–8080. https://doi.org/10.2147/CMAR.S162784
Ren X, Duan L, He Q et al (2010) Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med Chem Lett 1:454–459. https://doi.org/10.1021/ml100146z
Röllig C, Serve H, Hüttmann A et al (2015) Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol 16:1691–1699. https://doi.org/10.1016/S1470-2045(15)00362-9
Rudd SG, Tsesmetzis N, Sanjiv K et al (2020) Ribonucleotide reductase inhibitors suppress SAMHD1 ara- CTPase activity enhancing cytarabine efficacy. EMBO Mol Med 12:e10419. https://doi.org/10.15252/emmm.201910419
Russler-Germain DA, Spencer DH, Young MA et al (2014) The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25:442–454. https://doi.org/10.1016/j.ccr.2014.02.010
Schimmer AD, Jitkova Y, Gronda M et al (2012) A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies. Clin Lymphoma Myeloma Leuk 12:330–336. https://doi.org/10.1016/j.clml.2012.05.005
Serve H, Krug U, Wagner R et al (2013) Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 31:3110–3118. https://doi.org/10.1200/JCO.2012.46.4990
Sharma A, Jyotsana N, Lai CK et al (2016) Pyrimethamine as a potent and selective inhibitor of acute myeloid leukemia identified by high-throughput drug screening. Curr Cancer Drug Targets 16:818–828. https://doi.org/10.2174/1568009616666160617103301
Sharmeen S, Skrtic M, Sukhai MA et al (2010) The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood 116:3593–3603. https://doi.org/10.1182/blood-2010-01-262675
Shimada A (2019) Hematological malignancies and molecular targeting therapy. Eur J Pharmacol 862:172641. https://doi.org/10.1016/j.ejphar.2019.172641
Sidaway P (2018) Ivosidenib effective in IDH1-mutant AML. Nat Rev Clin Oncol 15:472–472. https://doi.org/10.1038/s41571-018-0057-4
Sigal DS, Miller HJ, Schram ED, Saven A (2010) Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 116:2884–2896. https://doi.org/10.1182/blood-2010-02-246140
Singh AA, Petraglia F, Nebbioso A et al (2018) Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. Oncotarget 9:25647–25660. https://doi.org/10.18632/oncotarget.25429
Škrtić M, Sriskanthadevan S, Jhas B et al (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20:674–688. https://doi.org/10.1016/j.ccr.2011.10.015
Song G, Wang L, Bi K, Jiang G (2015) Regulation of the C/EBPα signaling pathway in acute myeloid leukemia (Review). Oncol Rep 33:2099–2106. https://doi.org/10.3892/or.2015.3848
Stein EM, DiNardo CD, Fathi AT et al (2019) Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 133:676–687. https://doi.org/10.1182/blood-2018-08-869008
Stenvang J, Kümler I, Nygård SB et al (2013) Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front Oncol 3:313. https://doi.org/10.3389/fonc.2013.00313
Stone RM, Mandrekar SJ, Sanford BL et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454–464. https://doi.org/10.1056/NEJMoa1614359
Stratmann J, van Kann E, Rummelt C et al (2019) Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: a well-tolerated and effective treatment after hypomethylating-agent failure. Leuk Res 85:106192. https://doi.org/10.1016/j.leukres.2019.106192
Thomas X, Campos L, Mounier C et al (2005) Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 29:1049–1058. https://doi.org/10.1016/j.leukres.2005.02.010
Tibes R, Al-Kali A, Oliver GR et al (2015) The hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. J Hematol Oncol 8:114. https://doi.org/10.1186/s13045-015-0211-8
Tickenbrock L, Klein H-U, Trento C et al (2011) Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. Leuk Res 35:620–625. https://doi.org/10.1016/j.leukres.2010.11.006
Tremblay G, Cariou C, Recher C et al (2020) Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France. Eur J Health Econ 21:543–555. https://doi.org/10.1007/s10198-019-01149-9
Valli D, Gruszka AM, Alcalay M (2020) Has drug repurposing fulfilled its promise in acute myeloid Leukaemia? J Clin Med 9:1892. https://doi.org/10.3390/jcm9061892
van der Kouwe E, Staber P (2019) RUNX1-ETO: attacking the epigenome for genomic instable leukemia. Int J Mol Sci 20:350. https://doi.org/10.3390/ijms20020350
Verbaanderd C, Maes H, Schaaf MB et al (2017) Repurposing drugs in oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience 11:781. https://doi.org/10.3332/ecancer.2017.781
Wagner K, Damm F, Göhring G et al (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28:2356–2364. https://doi.org/10.1200/JCO.2009.27.6899
Wakimoto N, Yokoyama A, Okabe-Kado J et al (1998) Combined analysis of differentiation inhibitory factor nm23-H1 and nm23-H2 as prognostic factors in acute myeloid leukaemia. Br J Cancer 77:2298–2303. https://doi.org/10.1038/bjc.1998.382
Walf-Vorderwülbecke V, Pearce K, Brooks T et al (2018) Targeting acute myeloid leukemia by drug-induced c-MYB degradation. Leukemia 32:882–889. https://doi.org/10.1038/leu.2017.317
Walker A, Marcucci G (2012) Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. Expert Rev Hematol 5:547–558. https://doi.org/10.1586/ehm.12.45
Wallace JA, O’Connell RM (2017) MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts. Blood 130:1290–1301. https://doi.org/10.1182/blood-2016-10-697698
Wang F, Liu Z, Zeng J et al (2015) Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy. Leuk Res 39:1421–1427. https://doi.org/10.1016/j.leukres.2015.09.016
Watts JM, Baer MR, Yang J et al (2019) Olutasidenib (FT-2102), an IDH1m inhibitor as a single agent or in combination with azacitidine, induces deep clinical responses with mutation clearance in patients with acute myeloid leukemia treated in a phase 1 dose escalation and expansion study. Blood 134:231–231. https://doi.org/10.1182/blood-2019-123920
Wu H-C, Rérolle D, Berthier C et al (2021) Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy. Cancer Discov 11:3198–3213. https://doi.org/10.1158/2159-8290.CD-21-0177
Xia D, Zhang Y-T, Xu G-P et al (2017) Sertraline exerts its antitumor functions through both apoptosis and autophagy pathways in acute myeloid leukemia cells. Leuk Lymphoma 58:2208–2217. https://doi.org/10.1080/10428194.2017.1287358
Yan X-J, Xu J, Gu Z-H et al (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43:309–315. https://doi.org/10.1038/ng.788
Yokoyama A, Lin M, Naresh A et al (2010) A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17:198–212. https://doi.org/10.1016/j.ccr.2009.12.040
Zaidi SZ, Owaidah T, al Sharif F et al (2008) The challenge of risk stratification in acute myeloid leukemia with normal karyotype. Hematol Oncol Stem Cell Ther 1:141–158. https://doi.org/10.1016/S1658-3876(08)50023-9
Zhang H, Savage S, Schultz AR et al (2019) Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun 10:244. https://doi.org/10.1038/s41467-018-08263-x
Zhuang WY, Cen JN, Zhao Y, Chen ZX (2013) Epigenetic silencing of Bcl-2, CEBPA and p14ARF by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line. Oncol Rep 30:185–192. https://doi.org/10.3892/or.2013.2459
Zirm E, Spies-Weisshart B, Heidel F et al (2012) Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol 157:483–492. https://doi.org/10.1111/j.1365-2141.2012.09085.x
Acknowledgments
Nurdan Kelesoglu: conceptualization, writing—original draft preparation; Betul Yilmaz: review and editing, supervision; Kazim Yalcin Arga: conceptualization, review and editing, supervision. All authors have read and agreed to the published version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Author Disclosure Statement
The authors declare that no conflicting financial interests exist.
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kelesoglu, N., Karademir-Yilmaz, B., Arga, K.Y. (2022). Molecular Signatures in Acute Myeloid Leukemia: From Diagnosis to Targeted Therapy and Drug Repositioning. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2022_84
Download citation
DOI: https://doi.org/10.1007/16833_2022_84
Published:
Publisher Name: Springer, Cham